<DOC>
	<DOCNO>NCT00537563</DOCNO>
	<brief_summary>Clinical efficacy telithromycin moxifloxacin post-therapy/test cure visit , assess safety telithromycin give daily 5 day vs moxifloxacin give daily 10 day treatment subject AMS .</brief_summary>
	<brief_title>AMS VS MOXI Ketek v Avelox AMS</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Maxillary Sinusitis</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Adult subject , age 18 year old , AMS diagnose ( clinically radiologically ) willing undergo rhinoscopic aspiration deep nasal swab baseline/pretherapy visit . Female subject childbearing potential require negative pregnancy test undergoing study procedure use accept contraceptive method study . Women breastfeed pregnant , demonstrate serum urine pregnancy test carry exposure study medication start study procedure could pose risk fetus ; Subjects history recurrent sinusitis ( defined 3 episode sinusitis require antibiotic therapy precede 12 month ) ; Subjects history chronic sinusitis ( define symptom last great 28 day ) ; Subjects sphenoidal sinusitis involvement require treatment oral antibiotic ; Subjects nosocomialacquired sinusitis within 2 week ( eg , hospitalization nonambulatory , institutional confinement , include nurse home ) ; Subjects concomitant medication [ include functionally significant , major obstructive anatomical lesion likely impair resolution infection ( eg , nasal polyp extend past middle turbinate , tumor , severe septal deviation ) ] , : asthma , cystic fibrosis , immotile cilium syndrome , prior nasopharyngeal sinus surgery , sinus polyp , clinically relevant cardiovascular ( eg , congestive heart failure ) , neurologic , endocrine , major systemic disease could make implementation protocol interpretation study result difficult ; Subjects need immediate surgery maxillary sinusitis ; Subjects use nasal , nasogastric , nasotracheal catheter ; Subjects previous sinus surgery within past 6 month sinus lavage within past 7 day ; Subject longterm ( &gt; = 4 week ) user nasal decongestant like oxymetazoline 0.05 % ; Subjects suspect nonbacterial infection ; Subjects concomitant odontological infection would require antibiotic therapy surgery ; Subjects unknown suspected hypersensitivity , know suspect serious adverse reaction either study medication , fluoroquinolone , macrolide antibiotic ; Subjects would likely require onstudy treatment drug know contraindicated drug interaction either study medication and/or macrolides fluoroquinolones general , include , limited : ergot alkaloid derivative , cholinesterase inhibitor ( eg , tacrine , donepezil , physostigmine ) ketamine , carbamazepine , St John 's Wort , Class IA ( eg , quinidine , procainamide ) , Class III antiarrhythmic agent ( eg , amiodarone , sotalol ) ; Subjects require anticoagulant therapy ( eg , warfarin ) ; Subjects receive treatment systemic antibiotic ( oral parenteral ) within 14 day prior study enrollment ; Subject receive moxifloxacin another fluoroquinolone antibiotic infectious episode ; Likelihood require treatment study period drug permit protocol ; Treatment investigational product last 1 month prior study entry ; Subjects progressively fatal disease ; life expectancy &lt; le = 3 month ; Clinically relevant cardiovascular , hepatic , neurologic , endocrine , major systemic disease make implementation protocol interpretation study result difficult ; History drug alcohol abuse ; Impaired hepatic function [ show previous clinical laboratory value AST ( SGOT ) and/or ALT ( SGPT ) &gt; = 3 time upper limit reference range , total bilirubin &gt; 2 time upper limit reference range ( except Gilbert 's disease ) , encephalopathy , etc ] ; Impaired renal function [ show previous clinical laboratory value creatinine clearance &lt; = 30 mL/min ( &lt; = 0.50 mL/sec ) , serum creatinine &gt; = 2.0 mg/dl ( &gt; = 176 micromol/L ) , etc ] . Creatinine clearance may estimate formula nomogram ; Immunocompromised subject , subject HIV infection either AIDSdefining condition ( eg , Kaposi 's sarcoma Pneumocystis carinii pneumonia ) , CD4 + Tlymphocyte count &lt; 200/mm3 ) . A complete list provide Appendix 3 clinical study protocol ( see @ @ Appendix A.1.1 ) . subject neutropenia ( &lt; 1500 neutrophils/mm3 ) attributable acute infectious disease subject metastatic hematological malignancy splenectomised subject know hyposplenia asplenia subject know IgG deficiency Subject know long QT syndrome familiar history long QT syndrome ( previous ECG invalidate risk factor ) , personal history coronary disease , ventricular arrhythmia , bradycardia &lt; 50 beats/min , know uncorrected hypokalemia hypomagnesemia , treat concomitant medication know prolong QT interval ( eg , cisapride , pimozide , astemizaole , terfenadine , potent CYP3A4 inhibitor , : protease inhibitor , ketoconazole ) ; Mental condition render subject unable understand nature , scope , possible consequence study ; Subjects diagnose myasthenia gravis ( ie , Protocol Amendment No . 1 ) ; Subjects unlikely comply protocol ( eg , uncooperative attitude , inability return followup visit , unlikely complete study ) ; Subjects without permanent residential address home telephone number ; Any waiver inclusion/exclusion criterion approve investigator Aventis casebycase basis , prior study enrollment . This documented investigator Aventis ; No subject allow enroll study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>